CASP3 and neoplasm: Tumor cell proliferation, quantified by Ki67 immunostaining, was decreased in Losartan-treated animals (Figure 1c, P < 0.05), although no significant changes were observed in cleaved caspase 3 expression in tumors of Losartan-treated animals (Figure 1d, 0.5% in controls versus 1% in Losartan-treated).